References
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003;49:7–18.
- McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, and for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–4.
- Smidt N, Overbeke J, de Vet H, Bossuyt P. Endorsement of the STARD statement by biomedical journals: survey of instructions for authors. Clin Chem 2007;53:1983–5.
- Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF
- Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525–38.
- Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, Apple FS, Francis G, Tang W. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007;53:552–74.
- Apple FS. A new season for cardiac troponin assays: It's time to keep a scorecard. Clin Chem 2009;55:1303–6.
- Apple FS, Collinson PO, for the IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. Forthcoming 2012;58.
- Apple FS. Standardization of cardiac troponin I assays will not occur in my lifetime. Clin Chem. Forthcoming 2012;58.
- Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542–7.
- Chun FK, Karakiewicz PI, Briganti A, Walz J, Kattan MW, Huland H, Graefen M. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007;99: 794–800.
- Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52: 59–64.
- Stephan C, Siemßen K, Cammann H, Friedersdorf F, Deger S, Schrader M, Miller K, Lein M, Jung K, Meyer HA. Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. Clin Chem 2011;57:995–1004.
- Chun FKH, Graefen M, Briganti A, Gallina A, Hopp J, Kattan MW, Huland H, Karakiewicz PI. Initial biopsy outcome prediction—head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007; 51:1236–43.
- Stephan C, Meyer HA, Cammann H, Lein M, Loening SA, Jung K. Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction—head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236–43. Eur Urol 2007;51:1446–7.